Assay News and Research

RSS

Corning acquires Plaslab

Corning Incorporated announced today that it has completed the previously announced acquisition of all outstanding shares of Plaslab S.A.S. from certain investment funds managed by Qualium Investissement and from the other shareholders of Plaslab. Plaslab is the holding company of Plastiques Gosselin.

4 Oct 2010

NIH funds $1.5M for research into prediction of stroke risk in pediatric patients with sickle cell disease

A researcher from the biomedical engineering department operated by Georgia Tech and Emory University has received a $1.5 million NIH Director's New Innovator Award to support a project aimed at reducing the incidence of stroke in children with sickle cell disease. Manu Platt, an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering, will use the National Institutes of Health (NIH) funding to develop models for identifying which children with the disease are at risk for stroke.

1 Oct 2010

Health Canada approves Meridian Bioscience's illumigene C. difficile molecular amplification assay

Meridian Bioscience, Inc., today announced that it has received an approved medical device license from Health Canada for its new molecular amplification assay, illumigene C. difficile. Clostridium difficile is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon.

1 Oct 2010

Agilent introduces SureSelect Kinome Target Enrichment Kit to focus next-generation sequencing studies

Agilent Technologies Inc. today introduced the SureSelect Kinome Target Enrichment Kit, enabling researchers to focus next generation sequencing studies on expressed kinases (the kinome). Researchers increasingly are looking at human kinases as a rich, proven source of biomarkers as well as potential drug targets for cancers and other diseases.

30 Sep 2010

New miRNA screening assay to detect early-stage colorectal cancer

A new microRNA (miRNA) screening assay detected the majority of early-stage colorectal cancers with good specificity and sensitivity. Our test has the potential to be safe, cheap, robust, accurate and of little or no inconvenience to the individual, and could, therefore, easily be integrated into national screening programs as part of an annual checkup,said Søren Jensby Nielsen, Ph.D., scientific manager, Diagnostic Product Development, Exiqon A/S

30 Sep 2010

MicroRNAs assay may allow better targeted therapy for lung cancer patients

A test based on a panel of microRNAs under development by Rosetta Genomics, Ltd., in Rehovot, Israel, may allow for more precise diagnosis and better targeted therapy for patients with lung cancer.

30 Sep 2010

Bayer Schering collaborates with Ligon to apply SMM technology for first-in-class drug discovery

Ligon Discovery, the innovator of Small Molecule Microarray technology, today announced that it has partnered with Bayer Schering Pharma AG, Germany, to apply its proprietary Small Molecule Microarray screening platform (SMM) to discover potential first-in-class drug candidates for new disease targets.

29 Sep 2010

Scientists develop NIA assay to determine drug's differential effects in tumor cells

A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work.We are making progress toward the goal of understanding how drugs work in different individuals, said Alice C. Fan, M.D., instructor in the division of oncology at Stanford University School of Medicine.

29 Sep 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

Rockland receives Phase I SBIR grant to develop assay for monitoring Akt pathway activity

Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, assay development and preclinical studies, today announced that it has received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop a pharmacodynamic assay to monitor the Akt/mTOR signaling pathway.

28 Sep 2010

Asuragen announces results of study evaluating RNA-based assay for detection of common NPM1 mutations

Asuragen, Inc. announced today the results of a collaborative study with scientists at Johns Hopkins University School of Medicine evaluating a RNA-based assay for the rapid, sensitive and multiplex detection of common NPM1 mutations. The study results were published in the September issue of the Journal of Molecular Diagnostics.

23 Sep 2010

Evotec AG collaborates with Almirall for ion channel validation in respiratory diseases

Evotec AG today announced that it has entered into a collaboration with Almirall S.A. to identify small molecule modulators of an ion channel target, selected by Almirall, involved in respiratory diseases.

23 Sep 2010

Diagenode releases two monoclonal antibodies to enrich 5-hmC epigenetics research

Diagenode announced today that it has released two additional 5-hmC antibodies to complement its original 5-hmC (rat) monoclonal antibody. The two new 5-hmC monoclonal antibody (mouse) and polyclonal antibody (rabbit) antibodies give researchers additional choices for enriching and analyzing 5-hmC in their methylation studies.

23 Sep 2010

MDI and Integrated Sciences enter exclusive distribution agreement for Detect-Ready MRSA assay in Australia

Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, and Integrated Sciences Pty. Ltd. today announced that they have entered into an exclusive distribution agreement for MDI's Detect-Ready MRSA assay in Australia.

22 Sep 2010

Gen-Probe submits PMA to FDA for PROGENSA PCA3 assay

Gen-Probe announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its PROGENSA® PCA3 assay, a new molecular test that may help determine the need for repeat biopsies in men suspected of having prostate cancer.

22 Sep 2010

Health Canada issues license for IgX PLEX Celiac test kit

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, announced today that Health Canada has issued a medical device license for its automated IgX PLEX Celiac(TM) microarray test kit that runs on the Company's automated SQiDworks(TM) platform. The license allows the Company to market and sell the IgX PLEX Celiac product in Canada.

21 Sep 2010

Dominion validates clinical urine drug monitoring assay to detect metabolites of 'herbal incense' product compounds

Dominion Diagnostics has recently developed and validated one of the first clinical urine drug monitoring assays to detect the metabolites of JWH-018 and JWH-073, two compounds typically found in synthetic cannabinoids, also referred to as "herbal incense" products.

20 Sep 2010

Celldex commences CDX-011 Phase 2b trial in advanced breast cancer patients expressing GPNMB

Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company's CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, and brain tumors.

20 Sep 2010

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

Celera Corporation and Abbott today announced that they have signed an exclusive distribution agreement to market Celera's CE-marked KIF6 diagnostic test for use on Abbott's CE-marked m2000™ instrument system. The KIF6 genotyping assay detects a genetic marker that may be used in conjunction with clinical evaluation and patient assessment for the identification of individuals at risk for coronary heart disease (CHD), and in patients for whom statin treatment is being considered.

20 Sep 2010

Chronix Biomedical completes Series E financing

Chronix Biomedical today announced that it has completed a Series E financing that raised $1.8 million from existing and new investors. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix's serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.

20 Sep 2010

Assay News and Research

Corning acquires Plaslab

NIH funds $1.5M for research into prediction of stroke risk in pediatric patients with sickle cell disease

Health Canada approves Meridian Bioscience's illumigene C. difficile molecular amplification assay

Agilent introduces SureSelect Kinome Target Enrichment Kit to focus next-generation sequencing studies

New miRNA screening assay to detect early-stage colorectal cancer

MicroRNAs assay may allow better targeted therapy for lung cancer patients

Bayer Schering collaborates with Ligon to apply SMM technology for first-in-class drug discovery

Scientists develop NIA assay to determine drug's differential effects in tumor cells

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Rockland receives Phase I SBIR grant to develop assay for monitoring Akt pathway activity

Asuragen announces results of study evaluating RNA-based assay for detection of common NPM1 mutations

Evotec AG collaborates with Almirall for ion channel validation in respiratory diseases

Diagenode releases two monoclonal antibodies to enrich 5-hmC epigenetics research

MDI and Integrated Sciences enter exclusive distribution agreement for Detect-Ready MRSA assay in Australia

Gen-Probe submits PMA to FDA for PROGENSA PCA3 assay

Health Canada issues license for IgX PLEX Celiac test kit

Dominion validates clinical urine drug monitoring assay to detect metabolites of 'herbal incense' product compounds

Celldex commences CDX-011 Phase 2b trial in advanced breast cancer patients expressing GPNMB

Abbott to commercialize Celera's CE-marked KIF6 genotyping assay outside U.S.

Chronix Biomedical completes Series E financing

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News